No disease recurrences after short course of neoadjuvant immunotherapy, according to follow-up

A abbreviated people of neoadjuvant immunotherapy continues to amusement semipermanent outcomes successful patients with locally precocious mismatch repair–deficient (dMMR) colon cancer. In the NICHE-2 study, nary of the 111 patients successful the superior efficacy colonisation experienced illness recurrence, and each were live astatine their astir caller follow-up. The findings, present published successful The Lancet, supply further grounds of the durability of effect to neoadjuvant immunotherapy successful this diligent population.